This article was originally published in The Gray Sheet
Executive SummaryBoard of directors declares a dividend distribution of one common stock purchase right for each outstanding share of Tokos common stock. The rights, which the firm will issue on April 19, may be exercised if any person or group acquires or announces a tender offer for at least 20% of Tokos stock. Each right entitles the bearer to purchase newly issued shares that are worth twice the right's exercise price, which is $30. The board may redeem the rights for one cent each at any time before the tenth day following an entity's acquisition of 20% or more of the common stock. Tokos says that the rights, which expire in 10 years, "are not being distributed in response to any specific effort to acquire control of the company".
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.